Détection de la susceptibilité aux antibiotiques bactériens à l’aide d’un microscope à diffusion Raman stimulée

Executive Industry Relevance

Rapid detection of bacterial antibiotic susceptibility is critical for early-stage anti-infective discovery and translational research. Stimulated Raman scattering (SRS) microscopy enables quantitative, single-cell assessment of bacterial viability by measuring deuterium-labeled metabolic activity, supporting predictive confidence in antimicrobial screening. This approach accelerates decision-making at key inflection points in anti-infective portfolio development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct interrogation of bacterial metabolic response to candidate antibiotics.
• Supports functional validation of antimicrobial targets by quantifying viability shifts.
• Facilitates mechanistic de-risking through single-cell metabolic readouts.
• Improves predictive confidence for early-stage compound triage.

Screening & Assay Development

• Provides a rapid, quantitative assay for antibiotic susceptibility testing.
• Delivers reproducible, standardized outputs suitable for high-throughput workflows.
• Enables robust comparison of compound efficacy across bacterial populations.
• Supports assay scalability and platform reuse in anti-infective pipelines.

Translational & Preclinical Research

• Aligns metabolic viability measurements with translational biomarker strategies.
• Ensures continuity from discovery through preclinical validation of antimicrobial efficacy.
• Reduces biological risk by providing early, quantitative evidence of compound action.
• Supports risk-adjusted advancement decisions for anti-infective candidates.

Pipeline & Workflow Integration

This SRS-based method integrates into the anti-infective discovery continuum from early target validation through lead identification and preclinical assessment.

• Discovery Biology: Quantifies metabolic activity to test therapeutic hypotheses and clarify bacterial response pathways.
• Screening: Offers rapid, reproducible susceptibility readouts for compound evaluation.
• Analytics: Provides quantitative carbon–deuterium signal measurements for condition comparison.
• Translational Research: Bridges discovery and preclinical stages with biomarker-aligned viability data.
• Enterprise Reuse: Establishes a reusable platform for diverse antimicrobial screening campaigns.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in antimicrobial discovery.
• Operational Value: Delivers standardized, scalable, and reproducible susceptibility testing.
• Strategic Value: Enables faster go/no-go decisions and improves capital efficiency in anti-infective portfolios.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of candidate antibiotics.

Implementation Considerations

• Requires expertise in SRS microscopy and bacterial metabolic assays.
• Needs access to specialized imaging instrumentation and analytical infrastructure.
• Demands cross-team standardization of sample preparation and imaging protocols.
• May require adaptation for different bacterial species or resistance mechanisms.
• Dependent on quantitative signal analysis for robust susceptibility assessment.

Biopharma FAQs